Management of Pericarditis in Patients Taking Anticoagulants

Treatment Approach

The European Society of Cardiology recommends using low to moderate dose corticosteroids (prednisone 0.2-0.5 mg/kg/day) as the primary anti-inflammatory agent for patients with pericarditis who are taking apixaban, due to the high bleeding risk associated with combining anticoagulants and NSAIDs 1
Colchicine should be added as adjunctive therapy at a dose of 0.5 mg twice daily for patients ≥70 kg, and 0.5 mg once daily for patients <70 kg, and continued for at least 3 months to reduce recurrence risk 1, 2

The initial prednisone dose should be 0.25-0.5 mg/kg/day, with a taper schedule based on the initial dose:
Tapering should only occur when the patient is asymptomatic and CRP has normalized 1

The European Heart Journal recommends assessing response to therapy after 1 week, and monitoring CRP levels to guide treatment duration and assess response 1, 4
Treatment should be continued until symptoms resolve and CRP normalizes 1, 2

Temporary interruption of apixaban may be necessary for specific procedures related to pericarditis management, with discontinuation 24 hours before procedures with low bleeding risk, and 3 days before high bleeding risk procedures if creatinine clearance >30 mL/min 5
Apixaban should be resumed at least 6 hours after the procedure if hemostasis is achieved 5

For patients not responding to corticosteroids and colchicine, consider immunomodulatory agents such as azathioprine or IVIG, and IL-1 receptor antagonists (anakinra) have shown efficacy in refractory cases 1, 3
Pericardiectomy should only be considered as a last resort after failure of medical therapy 3

Calcium (1,200-1,500 mg/day) and vitamin D (800-1,000 IU/day) supplementation should be provided to all patients receiving glucocorticoids to prevent bone loss 3
Bisphosphonates should be considered for bone loss prevention in men ≥50 years and postmenopausal women on long-term glucocorticoid therapy 3